BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/27/2025 8:08:15 AM | Browse: 31 | Download: 47
 |
Received |
|
2025-07-23 02:03 |
|
Peer-Review Started |
|
2025-07-23 02:04 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-08-25 07:52 |
|
Revised |
|
2025-08-25 14:05 |
|
Second Decision |
|
2025-09-30 02:46 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-09-30 06:31 |
|
Articles in Press |
|
2025-09-30 06:31 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-10-21 01:46 |
|
Publish the Manuscript Online |
|
2025-10-27 08:08 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Editorial |
| Article Title |
Breaking barriers in the first-line Helicobacter pylori treatment: Chinese multicenter trial validates vonoprazan-based triple therapy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Vasily Isakov and Alexei Goncharov |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Ministry of Science and Higher Education of the Russian Federation |
FGMF-2025-0003 |
|
| Corresponding Author |
Vasily Isakov, MD, PhD, Professor, Department of Gastroenterology and Hepatology, Federal Research Center of Nutrition, Biotechnology and Food Safety, 21 Kashirskoe Shosse, Moscow 115446, Russia. vasily.isakov@gmail.com |
| Key Words |
Helicobacter pylori; First-line treatment; Vonoprazan; Triple therapy; Proton pump inhibitors |
| Core Tip |
This editorial highlights a pivotal multicenter randomized controlled trial from China demonstrating that vonoprazan (VPZ)-based triple therapy achieves superior or non-inferior Helicobacter pylori eradication rates compared to standard bismuth quadruple regimens, even in high clarithromycin resistance regions. The 10-day VPZ-amoxicillin-clarithromycin regimen exceeded 90% per-protocol efficacy with fewer adverse events, offering a simplified, well-tolerated alternative aligned with global treatment goals. These findings underscore a shift in empirical first-line therapy and support the integration of VPZ into updated regional and international guidelines. |
| Publish Date |
2025-10-27 08:08 |
| Citation |
<p>Isakov V, Goncharov A. Breaking barriers in the first-line Helicobacter pylori treatment: Chinese multicenter trial validates vonoprazan-based triple therapy. <i>World J Gastroenterol</i> 2025; 31(40): 112312</p> |
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i40/112312.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i40.112312 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
